IXICO plc Phase II HD contract with new client worth >$500K (2271M)
20 Septiembre 2021 - 01:00AM
UK Regulatory
TIDMIXI
RNS Number : 2271M
IXICO plc
20 September 2021
IXICO plc
("IXICO" or the "Company")
Phase II Huntington's disease contract award with new client
worth >$500K
IXICO plc (AIM: IXI), the AI data analytics company delivering
insights in neuroscience, announces that it has been awarded a
contract by a new US biopharmaceutical client to support its Phase
II Huntington's disease (HD) clinical trial . HD is a rare
condition of the nervous system that impacts the way people think,
behave, and move.
IXICO's proprietary Trial Tracker platform will be used to
collect, manage, and analyse MRI scans collected at 10 imaging
centres across the world.
The purpose of the trial is to evaluate the safety and
tolerability of the client's investigative therapy to determine
appropriate dose levels in patients with HD recruited into the
trial.
IXICO has been contracted as the specialist imaging vendor to
provide advanced neuroimaging solutions involving structural MRI,
as well as IXICO's patented LEAP, AI driven, analysis of the MRI
scans.
The study is anticipated to generate more than $500K of revenues
over twelve months.
Giulio Cerroni, Chief Executive Officer of IXICO, commented:
"Huntington's disease is a devastating rare neurological condition
with unmet medical needs. IXICO has worked on 16 HD clinical
studies since 2007 and we are pleased to build further momentum in
our mission to support our clients in identifying new insights into
this challenging rare, neurodegenerative disease. Our technology
services and AI data analytics enable clients to measure the impact
of the trialled drugs with greater confidence and potentially
unlock new insights into disease progression in support of much
needed new drug development ."
For further information please contact:
IXICO plc +44 (0)20 3763 7498
Giulio Cerroni, Chief Executive Officer
Grant Nash, Chief Financial Officer
Cenkos Securities PLC (Nominated adviser
and sole broker) +44 (0)20 7397 8900
Giles Balleny / Max Gould (Corporate
Finance)
Michael F Johnson / Russell Kerr
(Sales)
Walbrook PR Ltd +44 (0)20 7933 8780
Paul McManus / Lianne Cawthorne IXICO@walbrookpr.com
/
Alice Woodings
About IXICO
IXICO is dedicated to delivering insights in neuroscience. Our
purpose is to advance medicine and human health by turning data
into clinically meaningful information, providing valuable new
insights in neuroscience and our goal is to be a leading proponent
of artificial intelligence in medical image analysis. We will
achieve this by developing and deploying breakthrough data
analytics, at scale, through our remote access technology platform,
to improve the return on investment in drug development and reduce
risk and uncertainty in clinical trials for our pharmaceutical
clients.
More information is available on www.IXICO.com and follow us on Twitter @IxicOplc
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
CNTGPUBGBUPGPUB
(END) Dow Jones Newswires
September 20, 2021 02:00 ET (06:00 GMT)
Ixico (LSE:IXI)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Ixico (LSE:IXI)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024